Hypertension stage 1 (BP >140-159/90-99 mmHg) Circulatory System
Conditions
Interventions
Participants will be randomized with equal allocation to intervention and control groups. A computer-generated randomization will be used for random permuted blocks of 4, 6, or 8 to allocate participa
Sponsors
Center for Public Health Research
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of stage 1 HTN (BP >140-159/90-99 mmHg), which is based on the clinic and MOH definitions 2. Not currently taking HTN medication 3. Not having been on HTN medication in the past 3 months 4. Aged > 18 years and older
Exclusion criteria
Exclusion criteria: 1. Diagnosis of stage 1 HTN and currently taking HTN medication 2. Diagnosis of stage 2 HTN 3. Diabetes 4. History of recent myocardial infarction (in the past year) 5. Congestive heart failure 6. Complete heart block 7. Unstable angina 8. Glomerular Filtration rate of 90 or lower 9. Any pregnancy-associated HTN 10. Any limitation (e.g., limited hand mobility) preventing proper performance of IHT exercise 11. Any other condition that alters autonomic nervous system function
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean resting systolic BP will be measured using the validated automated Omron HEM-907XL device at baseline, 1, 2 and 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Mean resting diastolic BP measured using the validated automated Omron HEM-907XL device at baseline, 1, 2 and 3 months 2. The need for HTN medication measured using clinical guidelines and BP levels at 3 months 3. Safety outcomes (hospital admission for hypertensive crisis, severe (>180/110 mmHg), new myocardial infarction, transient ischemic attack, new embolic event) measured by a questionnaire and medical records throughout the 12 weeks of intervention 4. Intervention and control group adherence measured by IHT sessions attendance and monthly clinic visits throughout the 12 weeks of intervention 5. HTN medication adherence measured through self-report and pill counting at baseline, 1, 2 and 3 months 6. Sociodemographic and general health information measured by a questionnaire at baseline, 1, 2 and 3 months 7. Economic benefits of the intervention measured by tracking the cost of the intervention, guided in-person IHT sessions, healthcare utilization for HTN-related services, hypertensive medications, and transport to the clinic throughout the 12 weeks of intervention 8. Knowledge, attitudes, and practices (KAP) about HTN measured by a questionnaire at baseline and 3 months 9. Experience with IHT measured by a questionnaire at 3 months 10. Acceptability of IHT and home-based IHT measured by a semi-structured interview at 3 months | — |
Countries
Uganda
Contacts
Public ContactKate Zinszer
Outcome results
None listed